CGTX logo

COGNITION THERAPEUTICS INC

CGTXNASDAQ
πŸ† #4134 by market capEarnings Mar 25US Equity
β€”β€”
Quote unavailable
πŸ””
Track CGTX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$55M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for CGTX.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.55 – $1.81
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
95.1M
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-3.4
P/S Ratio
0.0x
EPS (TTM)
$-0.17
Dividend Yield
0.00%
Dilution (1yr)
+91.5%
CGTX logo

COGNITION THERAPEUTICS INC

CGTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$48Mβ–Ό βˆ’11.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$25Mβ–Ό βˆ’13.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.9Mβ–² +91.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$36Mβ–² +$12M YoY
StockOtter Β· stockotter.space

About COGNITION THERAPEUTICS INC

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathiesβ€”a category of diseases encompassing DLB and Parkinson's diseaseβ€”and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·5d ago

Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study

- Efficient screening processes may reduce participant and site burden in clinical trials - PURCHASE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a cli

Zacks Investment ResearchΒ·12d ago

What Makes Cognition Therapeutics (CGTX) a New Buy Stock

Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWireΒ·13d ago

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

PURCHASE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.Β (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the β€œCompany” or β€œCognition”),

Seeking AlphaΒ·16d ago

Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript

Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript

MarketBeatΒ·17d ago

Cognition Therapeutics Q3 Earnings Call Highlights

Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug Administration on a planned regist

GlobeNewsWireΒ·17d ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update

PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the β€œCompany” or β€œCognition”),